Clinical trial · Interventional
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Dose-reduced Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma and Myeloma
NCT06892119CI-TRIAL-00087762completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Generic plerixafor use at reduced-dose for mobilization on HSCT transplant
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Celrixafor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Generic plerixafor
- description
- Use a reduced-dose of generic plerixafor (0.12 mcg/Kg)
- interventionNames
- Drug: Celrixafor
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Use of a subcutaenous application of saline solution
- interventionNames
- Drug: Celrixafor
Primary outcomes (1)
- measure
- Post-RD plerixafor increase in CD34+/μL pre-count, final CD34+ cell yield and harvest
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with lymphoma or multiple myeloma who are candidates for autoHSCT * Patients \> 18 years old who signed our informed consent * Normal CBC count (Hb \> 10, WBC 4.0-11.00, plt \> 100,000) Exclusion Criteria: * Patients with HIV, Hepatitis C, Hepatitis B diagnosis * Pregnant women
References
Publications (1)
- RESULTGutierrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mejia-Jaramillo G, Salazar-Riojas R, Leon AG, Colunga-Pedraza PR, Sotomayor-Duque G, Jaime-Perez JC, Cantu-Rodriguez OG, Del Carmen Tarin-Arzaga L, Flores-Jimenez JA, Gomez-Almaguer D. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. Transfusion. 2019 Dec;59(12):3721-3726. doi: 10.1111/trf.15547. Epub 2019 Oct 16. PMID 31618456